Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm, Duke to Apply Metabolomics to Cardiovascular Drug Discovery

NEW YORK, Feb. 25 - Paradigm Genetics and researchers at the Duke University Medical Center have signed a multi-year research collaboration that seeks to apply metabolomics to drug discovery and development, Paradigm said on Monday.

Terms of the agreement call for Paradigm and the DUMC initially to research cardiovascular disease to identify and validate drug targets and to hunt for new biomarkers that may be used in predictive medicine. Studies are set to begin this quarter.

The research, which will extend beyond cardiovascular disease as the collaboration moves ahead, will bring together cardiology researchers at the university with Paradigm's metabolomics platform, MetaVantage.

"By bringing together [DUMC's] cardiologists with our ... experts in metabolomics, we believe we will identify new and better ways to diagnose and treat cardiovascular disease," John A. Ryals, Paradigm Genetics' president and CEO, said in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.